ProMetic Increases Its Ownership Stake in NantPro BioSciences, LLC ("NantPro")

--  NantPro's product to target $4 billion Intravenous Immunoglobulin
    ("IVIG") US market

--  ProMetic regains majority equity stake and board control of NantPro 

--  ProMetic to drive the IVIG development program; IND filing in 2014

--  Rights in connection with other plasma-derived product under development
    with NantPharma, LLC assigned to ProMetic; financial consideration to be
    rolled into NantPro



ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the
"Corporation") announced today that it has increased its ownership in NantPro
following the amendment of its related corporate and commercial agreements with
NantPharma, LLC ("NantPharma"). The amended agreements provide ProMetic back
with the effective control of NantPro and a greater portion of the future value
and revenues associated with the development and sales of IVIG in the US market.


Pursuant to the original agreements and NantPharma's expected additional capital
contribution, ProMetic's equity ownership position in NantPro LLC would have
been diluted down to 10% upon filing of the Investigational New Drug ("IND")
application for IVIG expected to take place in the second half of 2014. As a
result of the revised and amended agreements, ProMetic's equity position in
NantPro now exceeds 60%, and said position shall further increase by the time
this milestone is achieved.


This follows the recent announcement of the successful Pre-Investigational New
Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA")
focusing on ProMetic's proprietary Plasma Protein Purification System
("PPPS(TM)") manufacturing process as well as the clinical and regulatory
pathway for IVIG. 


"Regaining control of NantPro and its IVIG development program is representative
of our transition towards becoming a vertically integrated specialty
biopharmaceutical company. As we step up our manufacturing and development
activities, we anticipate advancing ourselves more of our high value
plasma-derived therapeutics", stated Pierre Laurin, President and Chief
Executive Officer of ProMetic. 


"While NantPharma will remain a significant partner in this venture, the NantPro
related development programs and operations are now being driven by ProMetic. We
strongly believe that the decision to forego some short term development
revenues for this product in order to take a majority share of equity in NantPro
will translate into significant gains in future revenues and value for all our
shareholders", mentioned Mr. Bruce Prichard, Chief Financial Officer of
ProMetic. "This initiative is in line with the previously disclosed use of
proceeds of our recent financings and strategy to continue partnering some of
our products but at greater value following the strengthening of our market
capitalization and balance sheet", added Mr. Pritchard. 


The production of GMP bioequivalence clinical trial material is currently
underway in ProMetic's plasma purification facility and the Corporation expects
to commence enrolling patients for the clinical trial in the fourth quarter of
2014. Following its Pre-IND meeting, Prometic is targeting market approval in
the US for IVIG in the second half of 2017.


As part of the NantPro restructuring, NantPharma has assigned to ProMetic all of
its intellectual property rights in connection with another plasma derived
biopharmaceutical product under development with ProMetic. The parties have
agreed that some financial considerations related to said product will be rolled
into NantPro. ProMetic remains responsible for the development and manufacturing
of this second plasma derived biopharmaceutical product, for which the current
global market is estimated to be worth $500M per year.


About IVIG

Intravenous immunoglobulin (IVIG) is a blood product administered intravenously.
It contains the pooled, polyvalent, IgG antibodies extracted from the plasma of
over one thousand blood donors. IVIG's effects last between 2 weeks and 3
months. It is mainly used as treatment in immune deficiencies, autoimmune
diseases and acute infections. The current global market for IVIG is estimated
to be worth in excess of $8 billion per year; with the US market representing an
estimated $4 billion per year.


About PPPS(TM) 

The Plasma Protein Purification System (PPPS(TM)) allows for the targeting and
removal of multiple high-value proteins from a single plasma sample at
unprecedented activity levels using ProMetic's Mimetic Ligand(TM) adsorbent
technology. This system also provides for the recovery of new biotherapeutics as
they are discovered and identified. The effect of this process is to reduce the
significant losses incurred when using the more conventional Cohn precipitation
process.


About ProMetic Life Sciences Inc. 

ProMetic Life Sciences Inc. (www.prometic.com) is a long established
biopharmaceutical company with globally recognized expertise in bioseparations,
plasma-derived therapeutics and small-molecule drug development. ProMetic offers
its state of the art technologies for large-scale purification of biologics,
drug development, proteomics and the elimination of pathogens to a growing base
of industry leaders and uses its own affinity technology that provides for
highly efficient extraction and purification of therapeutic proteins from human
plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic
is also active in developing its own novel small-molecule therapeutic products
targeting unmet medical needs in the field of fibrosis, cancer and autoimmune
diseases/inflammation. Headquartered in Laval (Canada), ProMetic has R&D
facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK
and business development activities in the U.S., Europe and Asia. 


Forward Looking Statements 

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations in ProMetic's Annual Information Form for the year ended December
31, 2013, under the heading "Risk and Uncertainties related to ProMetic's
business". As a result, we cannot guarantee that any forward-looking statement
will materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of future
events or for any other reason, unless required by applicable securities laws
and regulations. All amounts are in Canadian dollars unless indicated otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.
[e-mail]
+1.450.781.0115


Frederic Dumais
Director, Communications and
Investor Relations
ProMetic Life Sciences
[e-mail]
+1.450.781.0115